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Summary
 
The mechanism by which HIV-1 induces CD4
 
1
 
 T cell death is not known. A fundamental is-
sue is whether HIV-1 primarily induces direct killing of infected cells or indirectly causes death
of uninfected bystander cells. This question was studied using a reporter virus system in which
infected cells are marked with the cell surface protein placental alkaline phosphatase (PLAP).
Infection by HIV-PLAP of peripheral blood mononuclear cells (PBMCs) and T cell lines leads
to rapid depletion of CD4
 
1
 
 T cells and induction of apoptosis. The great majority of HIV-
induced T cell death in vitro involves direct loss of infected cells rather than indirect effects on
uninfected bystander cells. Because of its proposed role in HIV-induced cell death, we also ex-
amined the Fas (CD95/Apo1) pathway in killing of T cells by HIV-1. Infected PBMCs or
CEM cells display no increase in surface Fas relative to uninfected cells. In addition, HIV-1
kills CEM and Jurkat T cells in the presence of a caspase inhibitor that completely blocks Fas-
mediated apoptosis. HIV-1 also depletes CD4
 
1
 
 T cells in PBMCs from patients who have a
genetically defective Fas pathway. These results suggest that HIV-1 induces direct apoptosis of
infected cells and kills T cells by a Fas-independent mechanism. 
 
D
 
espite significant advances in our understanding of the
pathogenesis of AIDS, the mechanism by which hu-
man immunodeficiency virus 1 (HIV-1) infection induces
CD4
 
1
 
 T lymphocyte depletion is not known. Recent
studies indicate that turnover of both HIV-1 and CD4
 
1
 
 T
cells is extremely rapid (1–3) and that the viral load soon af-
ter infection predicts the rate of CD4
 
1
 
 T cell loss and the
development of AIDS (4). These observations suggest that
active HIV-1 replication drives the loss of CD4
 
1
 
 T lym-
phocytes. However, there are important gaps in our knowl-
edge of how HIV-1 causes this loss of T cells.
The fundamental issue of whether HIV-1 predominantly
kills infected cells or induces death of uninfected cells re-
mains controversial. This debate was initially prompted by
the low frequency of HIV-infected cells detected in vivo,
which led to a search for indirect causes of T cell depletion
(5). Indirect mechanisms of bystander T cell death could
include the following: syncytium formation between in-
fected and uninfected cells; aberrant T cell signaling due to
binding of free gp120 to CD4 and cross-linking by anti-
gp120 antibodies; triggering of apoptotic pathways in unin-
fected cells by soluble HIV-1 gene products or by infected
macrophages expressing Fas ligand; or cytokine dysregula-
tion, such as overproduction of TNF-
 
a
 
, leading to T cell
death (5–7). However, given the rapid turnover of CD4
 
1
 
T cells, it is possible that direct killing by HIV-1 leads to
depletion without requiring that a high percentage of cells
be productively infected at any given point in time. There-
fore, to understand the pathogenesis of AIDS, it is impor-
tant to know the extent to which HIV-induced T cell
death involves direct loss of infected cells versus indirect
killing of uninfected bystander cells.
The process by which cells die has generally been di-
vided into apoptosis and necrosis based upon morphologic
and biochemical criteria. There is accumulating evidence
that T cell apoptosis is increased in patients with HIV-1 in-
fection. PBMCs from HIV-infected patients undergo apop-
tosis in culture or after activation at a higher rate than PBMCs
from uninfected controls (8–10). Increased apoptosis is also
seen in lymph nodes from patients with HIV-1 infection
(11, 12). In animal models, increased T cell apoptosis is
seen in SIV-infected macaques, which develop an AIDS-
like syndrome, but not in HIV-infected chimpanzees,
which rarely develop immunodeficiency (13, 14). How-
ever, in these studies both CD4
 
1
 
 and CD8
 
1
 
 T cells are af-
fected (8, 13), raising the question of whether the increased
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apoptosis is directly due to HIV-1 infection or due to indi-
rect consequences of the disease.
The Fas/Fas ligand (FasL)
 
1
 
 system is a key cellular apop-
totic pathway that has been proposed to play a role in HIV-
induced cell death (15). This pathway is important in regu-
lation of lymphocyte survival and in antigen-induced T cell
death (16). Since T cell activation augments HIV-induced
apoptosis, the Fas pathway has been examined in patients
with HIV-1. Infected patients have a higher percentage of
Fas-expressing T cells as compared with uninfected people
(17), and T cells from these patients are more sensitive to
killing by anti-Fas antibody (15). In addition, FasL mRNA
levels have been found to be elevated in PBMCs from pa-
tients with HIV-1 infection (18). Soluble exogenous Tat
combined with CD4 cross-linking by antibody has been
shown to increase FasL mRNA expression in uninfected
PBMCs
 
 
 
(19)
 
. 
 
Whether HIV-1 directly or indirectly affects
the Fas pathway is not settled because previous studies have
not measured Fas or FasL levels specifically in those cells
that are infected.
To clarify the mechanisms of HIV-induced cell death,
we used a reporter virus system in which a cell surface pro-
tein, placental alkaline phosphatase (PLAP), is expressed by
HIV-1, thereby marking infected cells in a culture. This
system allows us to distinguish direct from indirect effects
of the virus on its host cell. We show by TUNEL (TdT-
mediated dUTP nick-end labeling) assay that HIV-1 infec-
tion induces apoptosis in T cell lines and primary T cells in
vitro. The reporter virus system is then used to show that
HIV-1 induces apoptosis predominantly in infected cells.
Finally, we use the reporter virus system to study the spe-
cific effects of viral infection on the Fas pathway. We find
that HIV-1 infection does not specifically upregulate Fas
expression on the surface of infected cells and that HIV-1 is
able to kill T cells in which the Fas pathway is defective or
cells in which the downstream effectors of the pathway are
blocked.
 
Materials and Methods
 
Cells.
 
CEM is a human CD4
 
1
 
 T lymphoblastoid cell line
originally isolated from a child with acute leukemia (20, 21).
SupT1 is a CD4
 
1
 
 T cell line isolated from a pleural effusion of a
non-Hodgkin’s lymphoma patient (22). Jurkat clone E6 is a
CD4
 
1
 
CD3
 
1
 
 acute T cell leukemia line (23). CEM (from Peter L.
Nara), SupT1 (from James Hoxie), and Jurkat clone E6 (from
Arthur Weiss) were obtained from the NIH AIDS Research and
Reference Reagent Program. The hFasL/L5178 cell line, which
stably expresses human FasL (hFasL; reference 24), was provided
by Hideo Yagita of the Juntendo University School of Medicine,
Tokyo, Japan. The CEM, SupT1, Jurkat, and hFasL/L5178 cell
lines were grown in RPMI 1640 medium supplemented with
 
10% fetal bovine serum, 100 U/ml penicillin, 100 
 
m
 
g/ml strepto-
mycin, and 2 mM glutamine. PBMCs from HIV-seronegative
blood donors were purified by centrifugation of buffy coat sam-
ples over a Ficoll-Hypaque (Pharmacia Biotech AB, Uppsala,
Sweden) density gradient. CD4
 
1
 
 T cells were purified by nega-
tive selection of PBMCs using a CD4
 
1
 
 T cell enrichment column
(R&D Systems, Minneapolis, MN) according to the manufac-
turer’s recommendations. Patients with autoimmune lymphopro-
liferative syndrome (ALPS) arising as a result of mutations in Fas
and their families were evaluated and followed at the Warren
Magnuson Clinical Center at the National Institutes of Health as
part of an Institutional Review Board–approved clinical research
protocol. PBMCs were isolated as above and T cells and EBV-
transformed B cells were tested for sensitivity to anti-Fas antibody
(CH11; Kamiya Biomedical, Seattle, WA) and plate-immobilized
anti-CD3
 
e
 
 monoclonal antibody (64.1) as previously described
(25, 26). PBMCs from these families were cryopreserved after
donation. Before infection with HIV-1, PBMCs and purified
CD4
 
1
 
 T cells were activated for 2 d in culture medium contain-
ing 5 
 
m
 
g/ml PHA (Sigma Chemical Co., St. Louis, MO), and
then maintained in culture medium with 100 U/ml recombinant
IL-2 (Genzyme Corp., Cambridge, MA).
 
Viruses.
 
The HIV molecular clone NL43 (27) was obtained
from Dr. Malcolm Martin through the AIDS Research and Ref-
erence Reagent Program. The HIV-1 molecular clone HXB2
was provided by Dr. Mark Feinberg (Emory University, Atlanta,
GA; R7 clone) and contains a repaired nef open reading frame
(28). The construction of PLAP-expressing NL43 (NL-PI) and
PLAP-expressing HXB2 (HXBnPLAP) have been previously de-
scribed (29, 30)
 
. 
 
Virus was produced by calcium phosphate trans-
fection of HIV DNA constructs into 293 cells and viral superna-
tants were harvested at 48 h after transfection as previously
described (30). Virus was quantitated by p24 ELISA to normalize
all infections to equivalent antigenic input (31).
 
Infections.
 
Target cells at 1–2 
 
3 
 
10
 
6 
 
cells/ml were incubated
with HIV-1 (NL43 or HXB2) or HIV-PLAP at different multi-
plicities of infection in the presence of 4 
 
m
 
g/ml polybrene for
8–12 h at 37
 
8
 
C in a humidified incubator. Infection of PBMCs
with HIV-PLAP was carried out by spin infection as follows: 1–2
 
3 
 
10
 
6 
 
cells in 1 ml of culture medium containing HIV-PLAP at
different multiplicities of infection and 4 
 
m
 
g/ml polybrene were
centrifuged in a sealed biosafety container for 90 min at 2,000
rpm in a Jouan CR4.12 centrifuge (Jouan Inc., Winchester, VA),
and then returned to a humidified incubator for 8–12 h. After in-
fection, cells were washed with 5 volumes of PBS and then resus-
pended in culture medium. Cultures were split every 2–3 d to
maintain a concentration of 5–20 
 
3 
 
10
 
5 
 
cells/ml. For experiments
involving the caspase inhibitor z-VAD-fmk (Enzyme Systems
Products, Livermore, CA), after infection CEM and Jurkat T cells
were resuspended in culture medium in the presence or absence
of 50 
 
m
 
M z-VAD-fmk. Cells were maintained at 5–20 
 
3 
 
10
 
5
 
cells/ml and fresh z-VAD-fmk was added every 2–3 d.
 
Flow Cytometry.
 
Flow cytometric analyses for PLAP and
CD4 were performed as previously described (30). In brief, cells
were stained with a 1:100 dilution of rabbit anti–human PLAP
(Zymed Laboratories, So. San Francisco, CA) and a 1:100 dilu-
tion of anti–human CD4-biotin (Caltag Labs., Burlingame, CA).
Goat anti–rabbit FITC that was human and mouse serum ad-
sorbed (BioSource International, Camarillo, CA) at 1:250 and
Ultra-avidin PE (Leinco Technologies, Ballwin, MO) at 1:100
were used as secondary stains. The control for the anti-PLAP
staining was incubation of cells with secondary antibody only.
Triple staining for CD3, CD4, and CD8 was done using anti-
 
1
 
Abbreviations used in this paper:
 
 ALPS, autoimmune lymphoproliferative
syndrome; FasL, Fas ligand; hFasL, human FasL; HXBnPLAP, PLAP-
expressing HXB2; NL-PI, PLAP-expressing NL43; PLAP, placental alka-
line phosphatase; TUNEL, TdT-mediated dUTP nick end labeling. 
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CD3-FITC (PharMingen, San Diego, CA) at a 1:25 dilution,
anti-CD4-PE (Caltag Labs.) at a 1:100 dilution, and anti-CD8-
CyChrome (PharMingen) at a 1:25 dilution. Two-color staining
for surface PLAP and Fas was performed using rabbit anti–human
PLAP as above and mouse anti–human Fas IgM (Upstate Bio-
technology, Inc., Lake Placid, NY) at a 1:200 dilution; secondary
staining was done with goat anti–rabbit PE (Southern Biotech-
nology Associates, Birmingham, AL) at 1:200 and goat anti-
mouse IgM FITC (Caltag) at 1:250. FasL staining was performed
using the NOK-1 antibody (PharMingen) at 20 
 
m
 
l per reaction
followed by biotin-conjugated goat anti–mouse immunoglobulin
(PharMingen) at 1:100 and then Ultra-avidin PE at 1:100. Cells
that were stained for FasL were grown and stained in the presence
of 10 
 
m
 
M of the metalloproteinase inhibitor KB8301 (24), which
was provided by Hideo Yagita. After staining, cells were fixed in
1% paraformaldehyde overnight. Flow cytometry was performed
on a FACScan
 
Ò
 
 (Becton Dickinson, San Jose, CA) as previously
described.
 
Detection of Cytopathicity and Apoptosis.
 
The number of viable
cells in each culture was determined by using trypan blue exclu-
sion. To perform two-color staining for PLAP and TUNEL, cells
were first stained for PLAP, and goat anti–rabbit PE was used as a
secondary stain as above. The cells were then fixed in 1%
paraformaldehyde for 1 h, washed in PBS, resuspended in 70%
EtOH, and stored overnight at 4
 
8
 
C. The cells were then washed
twice in PBS and a TUNEL assay was carried out using the In
Situ Cell Death Detection Kit, Fluorescein (Boehringer Mann-
heim, Indianapolis, IN) as per the manufacturer’s recommenda-
tions, except that the cells were permeabilized with 70% EtOH
(see above) rather than with Triton X-100. After the TUNEL re-
action, cells were washed in 20 volumes of PBS twice. Cells were
then analyzed by flow cytometry for both PLAP and TUNEL.
Apoptosis was also assessed by staining cells with propidium io-
dide for DNA content and by determining the percentage of cells
that had hypodiploid DNA content. Cells were permeabilized in
70% EtOH for 1 h, washed in PBS, and then resuspended in PBS
containing 0.1 mg/ml propidium iodide and 1 mg/ml RNAse.
After 90 min in the dark at room temperature the cells were ana-
lyzed by flow cytometry.
 
Results
 
Infection of T Cell Lines and Primary Cells with PLAP-
expressing HIV-1 Leads to CD4 Cell Depletion.
 
To study how
HIV-1 kills CD4
 
1
 
 T cells, we infected two human CD4
 
1
 
T lymphoblastoid cell lines, CEM and SupT1, with either
the HIV-1 molecular clone NL43 or NL-PI (Fig. 1 
 
A
 
), and
then determined the number of viable cells every 2–4 d.
We observed consistent depletion of both cell types in the
HIV-infected cultures by 7–10 d after infection (Fig. 2 
 
A
 
).
Although the reporter virus NL-PI grew more slowly than
did the wild-type virus (data not shown), it also induced
significant T cell depletion in these cells, thereby allowing
us to study the mechanism of HIV-induced T cell killing.
We also examined the effect of HIV-1 infection of
PHA-activated PBMCs from uninfected donors on the
percentage and absolute number of CD4
 
1
 
 T cells. After in-
fection with NL43 or NL-PI, a portion of each culture was
stained daily for surface CD3, CD4, and CD8 expression
and analyzed by flow cytometry. This method allowed us
to distinguish loss of CD4 cells from the CD4 downmodu-
lation induced by multiple HIV-1 gene products (30). CD4
downmodulation was detected by the appearance of CD3
 
1
 
CD4
 
2
 
CD8
 
2
 
 T cells in the culture, and these cells were in-
cluded in the determination of CD4
 
1
 
 
 
cells present in the
sample. We found that infection with NL43 led to a rapid
depletion of CD4
 
1
 
 T cells from the culture (Fig. 2 
 
B
 
).
Similar results were obtained with NL-PI (data not shown).
At early time points (2–3 d after infection), the extent of
depletion was proportional to the amount of virus added to
the culture (as measured by nanogram per milliliter of HIV
p24). When PBMCs were infected with 50 ng/ml p24 of
NL43 or 200 ng/ml p24 of
 
 
 
NL-PI, the majority of CD4
 
1
 
cells were lost within 2 to 4 d after infection.
We then asked whether depletion of primary CD4
 
1
 
 T
cells by HIV-1 depends upon the presence of other cells
because it has been suggested that macrophages may upreg-
ulate FasL after HIV-1 infection and then kill CD4
 
1
 
 T cells
expressing Fas (32). We purified CD4
 
1
 
 T cells to 
 
.
 
95%
purity using a column that removes CD8
 
1
 
 T cells, mac-
rophages and B cells. Infection of PHA-activated purified
CD4
 
1
 
 T cells with HXB2 led to rapid depletion of all the
cells in culture (Fig. 2 
 
C
 
), suggesting that HIV-1 can cause
the death of CD4
 
1
 
 T cells in the absence of other cell
types.
 
HIV-1 Infection Leads to Apoptosis by a Direct Mecha-
nism.
 
To determine whether
 
 
 
HIV-1 infection was killing
T cells by apoptosis, we performed a TUNEL assay on in-
fected and uninfected cell cultures. In both T cell lines and
primary CD4
 
1
 
 T cells, the cultures infected with HIV-1
had a significantly higher percentage of TUNEL-positive
cells as compared with an uninfected culture (Fig. 3, 
 
A
 
 and
Figure 1. Genomic organization of HIV constructs. NL-PI is derived
from NL43 and expresses all of the accessory genes of HIV-1. IRES indi-
cates insertion of an internal ribosomal entry site (from encephalomyo-
carditis virus) which restores expression of nef in NL-PI. HXBnPLAP is
derived from HXB-2D and does not express the accessory genes vpr, vpu
and nef. Gray boxes indicate genes expressed by the virus; open boxes in-
dicate genes that are not expressed. 
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B
 
). In purified CD4
 
1
 
 T cells, there was a sixfold increase in
apoptosis in the infected culture 5 d after infection.
We then determined whether infected or uninfected
cells within a culture are preferentially undergoing apopto-
sis by infecting cultures with HIV-PLAP and performing
two-color flow cytometric analysis for detection of PLAP
and TUNEL. After infection of both CEM and primary
CD4
 
1
 
 T cells with HIV-PLAP, a higher fraction of PLAP-
positive cells was TUNEL-positive as compared with PLAP-
negative cells (Fig. 4). In CEM cells, we infected 75.6% of
cells by day 4 after infection (Fig. 4 
 
B
 
, 
 
upper right
 
 plus 
 
lower
right quadrants
 
). The percentage of TUNEL-positive and
PLAP-positive cells was 16.1% (Fig. 4 
 
B
 
, 
 
upper right quadrant
 
).
Therefore, 21.3% (16.1 out of 75.6%) of infected (PLAP-
positive) cells were undergoing apoptosis (TUNEL-positive).
The percentage of TUNEL-positive and PLAP-negative
cells undergoing apoptosis was 1.7% (Fig. 4 
 
B
 
, 
 
upper left
quadrant
 
), which is comparable to the background apoptosis
in CEM cells. In purified CD4
 
1
 
 cells, we infected 7.75% of
cells by day 5 after infection and 1.94% of cells were
TUNEL- and PLAP-positive (Fig. 4 
 
E
 
). Thus, 25% (1.94
out of 7.75%) of infected (PLAP-positive) CD4
 
1
 
 
 
T cells
were undergoing apoptosis (TUNEL-positive). The frac-
tion of PLAP-negative
 
 
 
cells that were TUNEL-positive in
the infected culture was nearly the same as that in the unin-
fected culture (8%), which is the background apoptosis af-
ter activation of primary cells. A similar result was obtained
when primary cells were examined 3 d after infection (data
Figure 2. CD41 T cell depletion after infection with HIV-1. (A) SupT1 and CEM cells were infected with either NL43 or NL-PI or mock-infected
and the number of viable cells was determined by trypan blue exclusion on the indicated days after infection. (B) PBMCs from a normal donor were in-
fected with different concentrations of NL43 (measured in nanograms per milliliter of p24) or mock-infected. Samples were stained daily for CD3, CD4,
and CD8 and analyzed by flow cytometry. The percentage of CD41 cells remaining on each day is plotted. Cells that were CD31CD42CD82 were con-
sidered to have downregulated CD4 and were included in the percentage of CD41 T cells remaining. (C) CD41 T cells were purified from a normal do-
nor and infected with HXB2 or mock-infected. The number of viable cells was determined by trypan blue exclusion on the indicated days after infection.
All experiments were performed at least three times and representative results are shown.
Figure 3. TUNEL assay on infected and uninfected CD41 T cells. (A)
CD41 T cells from a normal donor were purified and infected with
HXB2 or mock-infected. TUNEL assays were performed 3 and 5 d after
infection. The TUNEL-positive gate was determined by analyzing each
sample in parallel without TdT in the TUNEL reaction mix. (B) CEM
and SupT1 cells were infected with NL43 or mock-infected and purified
CD41 T cells were infected with HXB2 or mock-infected. TUNEL as-
says were performed on days when the cell counts were declining. The
percentage of TUNEL-positive cells is plotted for CEM, SupT1 (both
day 6 after infection) and purified CD41 T cells (day 5 after infection).
These results are representative of three separate experiments.1117 Gandhi et al.
not shown). Therefore, in both CEM and primary CD41 T
cells, virtually all of the HIV-induced apoptosis occurs in
the infected population. We find in vitro that HIV-1 infec-
tion has little influence on levels of apoptosis occurring in
uninfected bystander cells.
HIV-1 Infection Does Not Upregulate Fas Surface Expres-
sion. The Fas pathway plays a key role in regulating the
survival of T lymphocytes, and induction of this pathway
has been proposed as a mechanism by which HIV-1 causes
T cell apoptosis. In PBMCs from HIV-infected patients, a
higher percentage of T cells express Fas, and the T cells are
more sensitive to killing by anti-Fas antibody (15, 17).
However, it is not known whether these effects are specific
to HIV-infected cells. Therefore, we examined whether
Fas expression is upregulated in HIV-infected cells by ana-
lyzing cultures infected with HXBnPLAP (Fig. 1 B) for ex-
pression of Fas and PLAP. PLAP-positive PBMCs did not
have an increase in surface Fas expression as compared with
PLAP-negative cells (Fig. 5). Infection with NL-PI also did
not affect surface expression of Fas on PBMCs when as-
sessed 4–9 d after infection (data not shown). Since NL-PI
expresses all of the regulatory genes of HIV-1, the lack of
Fas modulation was not due to the absence of a specific
HIV-1 gene product. Similar results were obtained when
CEM cells were infected with NL-PI (data not shown).
This finding suggests that HIV-1 does not specifically up-
regulate Fas expression on the surface of infected cells.
We also stained uninfected and infected CEM cells and
activated PBMCs for FasL. In uninfected cells, levels of
surface FasL were extremely low even in the presence of a
metalloproteinase inhibitor, which previously has been
shown to stabilize FasL on the cell surface (24). We ob-
served no difference in FasL levels in infected cultures as
compared with uninfected cultures (data not shown). As a
control, surface FasL was easily detected on hFasL/L5178Y
cells stably expressing hFasL (data not shown). The low
level of FasL detected on T cells makes it difficult to rule out
that HIV-1 infection subtly affects its surface expression.
HIV-induced Killing of T Cells Does Not Require the Fas
Pathway. We found that the ability of HIV-1 to induce
cell death in a T cell line was not correlated with the Fas
sensitivity of the cell line. As shown in Fig. 2 A, HIV-1 was
able to deplete both SupT1 and CEM cells although these
cells differ significantly in their susceptibility to Fas-induced
killing. This was shown by incubating SupT1 and CEM
cells with increasing amounts of anti-Fas antibody (CH11)
for 24 h and then staining with propidium iodide to deter-
mine their DNA content; the percentage of hypodiploid
cells was used as a measure of apoptosis. CEM cells under-
went apoptosis with small amounts of anti-Fas antibody,
whereas SupT1 cells were resistant to anti-Fas antibody
over a wide range of antibody concentration (Fig. 6). This
difference was not due to a lack of expression of Fas since
both CEM and SupT1 cells expressed Fas on their surface
(data not shown).
We also determined whether inhibiting caspases, which
are critical downstream effectors of the Fas pathway, would
block HIV-induced cell death. Z-VAD-fmk is a cell-per-
meable irreversible peptide inhibitor of multiple caspase
family members (33). When present at a concentration of
Figure 4. Two-color flow cytometric analy-
sis of cells for PLAP and TUNEL. CEM cells
(A–C) and purified CD41 T cells (D–F) were
mock-infected or infected with NL-PI. CEM
cells and purified CD41 T cells were stained 4
and 5 d after infection, respectively, for PLAP
and TUNEL. (A and D) uninfected cultures.
(B and E) Infected cultures. (C and F) Infected
cultures in which TdT was left out of the
TUNEL reaction mix. The percentage of cells
in each region is indicated in the corners of
each plot. These results are representative of
three separate experiments.
Figure 5. Two-color flow cytometric analysis of PBMC for Fas and
PLAP. (A) Uninfected cells. (B) PBMCs on day 6 after infection with
HXBnPLAP.1118 HIV-1 Directly Kills CD41 T Cells by a Fas-independent Mechanism
50 mM, z-VAD-fmk completely blocked apoptosis of CEM
T cells induced by 1 mg/ml of anti-Fas antibody (Fig. 7 A).
CEM cells were infected with HXBnPLAP in the presence
or absence of 50 mM of z-VAD-fmk. HIV-1 infection de-
pleted CEM T cells as rapidly in the presence of z-VAD-
fmk as in its absence (Fig. 7 B). HIV-PLAP also depleted
Jurkat T cells in the presence of z-VAD-fmk (data not
shown). In fact, we observed a more rapid depletion of Jur-
kat cells by HXBnPLAP when z-VAD-fmk was present.
Staining for PLAP demonstrated that Jurkat cells were
more rapidly infected by HIV-1 in the presence of z-VAD-
fmk (data not shown), as has been previously reported (34).
In CEM cells, the rate of infection was not significantly af-
fected by the caspase inhibitor. In these cells, z-VAD-fmk
decreased the percentage of TUNEL-positive cells from 37.7
to 15.5% on day 8 after infection (background apoptosis in
uninfected cells was ,2%). However, by day 10 virtually
all cells were killed by HIV-1 in the z-VAD-fmk–treated and
untreated cultures. Therefore, despite blocking Fas-induced
apoptosis and decreasing HIV-triggered DNA cleavage, the
caspase inhibitor did not prevent virus-associated depletion
of CEM cells. There was no effect of z-VAD-fmk alone on
growth of uninfected CEM or Jurkat cells.
Finally, we examined whether HIV-1 could kill CD41
T cells from patients who have a genetically defective Fas
signaling pathway. A number of patients with ALPS are
known to harbor heterozygous dominant-negative muta-
tions in the Fas molecule which renders them relatively in-
sensitive to killing by anti-CD3 stimulation or anti-Fas an-
tibody (25, 35, 36). Many of these patients have missense
mutations in the Fas death domain. We studied cells from
two ALPS patients and their healthy (Fas-normal) mothers
for susceptibility to HIV-induced cell death. These two
patients had mutations in exon 9 of the Fas gene that ren-
dered their T cells significantly less susceptible to anti-
CD3– and anti-Fas–induced killing (Table 1). We infected
PBMCs from these two ALPS patients and their healthy
mothers with serial dilutions of NL-PI. Using the PLAP
marker, we found that the percentage of infection is pro-
portional to the amount of input HIV over a range of 20–
200 ng/ml p24, and that after spin infection with the high-
est concentration of NL-PI, .75% of CD41 T cells are
infected after 1 d. Importantly, both normal and Fas path-
way–defective CD41 T cells were almost completely de-
Figure 6. Sensitivity of CEM and SupT1 cells to anti-Fas antibody.
Cells were incubated for 24 h in the presence of the indicated concentra-
tions of mouse anti–human Fas IgM antibody (CH11). The percentage of
apoptosis was assessed by staining the cells with propidium iodide and de-
termining the fraction of cells that had hypodiploid DNA content.
Figure 7. The effect of the caspase inhibi-
tor z-VAD-fmk on apoptosis induced by Fas
and on killing of T cells by HIV-1. (A)
Anti-Fas antibody (CH11) at 1 mg/ml was
added to the indicated samples of CEM T
cells that had been grown in the presence or
absence of 50 mM of z-VAD-fmk. At 18 h
after addition of anti-Fas antibody, the sam-
ples were analyzed for apoptosis by the
TUNEL assay. (B) CEM T cells were in-
fected with HXBnPLAP in the presence or
absence of 50 mM z-VAD-fmk. Fresh
z-VAD-fmk was added to the culture every
2 d. On the indicated days, equal sample
volumes were counted for 1 min on a FACS-
canÒ and the number of cells with forward
and side scatter characteristics consistent
with viable cells was determined. This num-
ber in infected samples is plotted as a frac-
tion of the number in the mock-infected
culture.1119 Gandhi et al.
pleted by day 7 after infection with NL-PI (Fig. 8). Similar
results were obtained when these cells were infected with
NL43 (data not shown). These results indicate that HIV-1
can kill primary cells that have a defect in their Fas pathway.
Discussion
The process by which HIV-1 induces CD41 T lympho-
cyte death was studied using a reporter virus system that
distinguishes direct from indirect effects of the virus on its
host cell. We find that, in vitro, T-tropic HIV-1 depletes
and induces apoptosis in CD41 primary cells and cell lines.
After infection of PBMCs with high titers of HIV-1,
.50% of CD41 T cells are depleted in 2–3 d. This finding
is in agreement with in vivo studies of viral dynamics that
indicate that the half-life of the infected cell is z2 d (3).
Earlier studies found a slower in vitro depletion of primary
CD41 T cells by HIV-1 (37); in those experiments HIV-1
was amplified by prolonged cultivation with producer cells,
possibly resulting in accumulation of less infectious viral
variants. We avoid this problem by producing HIV-1 by
transient transfection of 293 cells with viral DNA con-
structs, generating high titer, homogeneous HIV-1 able to
infect at high multiplicity.
We have used the PLAP reporter virus system to dem-
onstrate in vitro that HIV-1 directly induces apoptosis in
the cells that it infects. The majority of HIV-induced cell
death in vitro occurs in cells that have expressed the PLAP
marker. This result is important in light of the continuing
debate over whether HIV-1 directly kills infected cells or
whether it predominantly induces death of uninfected by-
stander cells (6). Our finding that in the context of viral in-
fection HIV-1 predominantly causes direct cell death ar-
gues against in vitro models in which isolated HIV-1 gene
products, such as Tat or Env, induce killing of uninfected
bystander cells (38–40). In addition, since HIV-1 is able to
directly kill purified primary CD41 T cells in the absence
of other cell types, the proposed upregulation of FasL on
infected macrophages and resulting parricide of uninfected
T cells (32) does not appear to be necessary to explain how
HIV-1 induces T cell death. Our demonstration in vitro
that HIV-1 directly kills infected cells is consistent with re-
cent indications that HIV-infected patients with different
degrees of immune dysfunction have similar rates of in-
fected cell clearance, suggesting that direct cytopathicity of
the virus determines the lifespan of the infected cell (1, 3, 41).
The finding that the majority of HIV-specific cell death
occurs in cells that express viral gene products appears to
contradict observations that in HIV-infected patients apop-
tosis is increased in CD81 T cells (8, 13) and B lympho-
cytes (42) as well as in CD41 T cells. We suggest that this
increased apoptosis may be due to the generalized immune
Table 1. Characteristics of Cells from Patients
Patient Fas genotype Cell type Treatment Percentage of killing
ALPS patient 3 A915C (Thr225 to Pro) EBV-transformed B cells anti-Fas Ab 11
13-yo M with ALPS T cells anti-Fas Ab 35
T cells anti-CD3 14
Mother of patient 3 WT EBV-transformed B cells anti-Fas Ab 41
T cells anti-Fas Ab 66
ALPS patient 27 C916A (Thr225 to Lys) T cells anti-Fas Ab 37
8-yo M with ALPS T cells anti-CD3 21
Mother of patient 27 WT T cells anti-Fas Ab 79
T cells anti-CD3 41
M, male; WT, wild-type; yo, year-old.
Figure 8. Fraction of CD41 T cells lost after HIV-1 infection of PBMCs
from patients with ALPS and normal controls. PBMCs from the patients
characterized in Table 1 were infected with 200 ng/ml p24 of NL-PI and
samples were stained daily for CD4 and PLAP. The fraction of CD41
cells loss compared with uninfected is 1 2 (percentage of CD41 cells in
the infected sample/percentage of CD41 cells in the uninfected sample).
Cells that were PLAP1 and CD4lo were considered to be infected cells
that had downmodulated CD4, and, thus, were included in the determi-
nation of CD41 cells present in the sample.1120 HIV-1 Directly Kills CD41 T Cells by a Fas-independent Mechanism
activation which occurs in response to HIV-1 infection
and, thus, may not be responsible for selective CD41 T cell
depletion. Other viral infections, such as with EBV, have
also been associated with increased apoptosis of uninfected
lymphocytes (43). In addition, a study that examined
lymph nodes of patients with and without HIV infection
concluded that the intensity of apoptosis correlated with
the generalized state of activation of the lymph node (i.e.,
the degree of follicular hyperplasia and germinal center for-
mation) and not with the stage of disease and viral burden
(12). The relative role of increased apoptosis secondary to
global immune activation in the pathogenesis of the selec-
tive CD41 T cell depletion in AIDS is not clear.
Because of its critical role in regulating lymphocyte sur-
vival, we also examined the importance of the Fas pathway
in HIV-induced cell death. This pathway has been pro-
posed to mediate HIV-induced cell death based in part on
observations that patients with HIV-1 infection have a
higher percentage of Fas-expressing lymphocytes than un-
infected people (17). However, our analysis demonstrates
that HIV-1 infection does not directly lead to upregulation
of Fas on the surface of the infected cell. Using the HIV-
PLAP reporter virus system to distinguish infected from
uninfected cells, we find that PLAP-positive primary T
cells and CEM cells have the same level of surface Fas as
PLAP-negative cells. The elevated percentage of PBMCs
expressing Fas in patients with HIV-1 infection may again
be a nonspecific manifestation of immune activation. Acti-
vation through the antigen receptor is known to induce
expression of Fas in T lymphocytes (44–46), and this could
explain why both CD81 and CD41 T cells from patients
with HIV-1 have been found to have elevated levels of sur-
face Fas (17).
Our findings also raise doubts as to whether the Fas
pathway is necessary for HIV-1 to kill CD41 T cells. Al-
though both CEM and SupT1 cells are efficiently killed by
HIV-1, only the CEM cells are sensitive to Fas-induced
killing. SupT1 cells are resistant to apoptosis induced by
anti-Fas antibody even though they express surface Fas.
HIV-1 infection also leads to rapid depletion of CD41 T
cells from the PBMCs of patients who have a dominant-
negative mutation in Fas that impairs Fas-mediated killing.
Since the cells from these patients have some residual Fas
function (Table 1), this finding does not rule out the possi-
bility that this pathway is involved in HIV-induced cell
death. However, we also find that HIV-1 kills CEM and
Jurkat T cells in vitro despite the presence of a caspase in-
hibitor (z-VAD-fmk) that completely abrogates Fas-medi-
ated apoptosis. In fact, we find, in agreement with a previ-
ous report (34), that the presence of z-VAD-fmk augments
the spread of HIV-1 through Jurkat T cell cultures, which
in turn leads to their more rapid death. The caspase inhibi-
tor does decrease the percentage of TUNEL-positive CEM
cells after HIV-1 infection, but it does not prevent virus-
induced depletion of these cells. This finding is analogous to
Bax-induced  apoptosis, in which z-VAD-fmk inhibits
DNA cleavage but does not block cell death (47). Similarly,
HIV-1 may induce cell death both by triggering caspases
that cause DNA cleavage as well as by activating other
pathways that lead to the death of the cell. These unknown
effectors allow HIV-1 to kill CD41 T cells even when the
Fas-induced caspases are inhibited. In conclusion, these re-
sults suggest that HIV-1 directly kills CD41 T lymphocytes
in vitro by a Fas-independent mechanism. The details of
this mechanism will be an important topic for future study.
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